LDN

Two New Research Studies Reinforce Prunes' Role in Optimal Health

Retrieved on: 
Jeudi, mai 9, 2024
Conditional sentence, Randomized controlled trial, Inflammation, Oxidative stress, Psyllium, News, Risk, Woman, Body mass index, Mineral, RDN, Health, Heart, BMI, CSSD, Doctor of Philosophy, Research, Vitamin, Osteoporosis, Diet, MPH, Vitamin K, Nutrient, Cardiovascular disease, Eating, Antioxidant, Pennsylvania State University, LDN, Ageing, Journal, Bone density, Frontiers, Muesli, Dietary supplement

ROSEVILLE, Calif., May 9, 2024 /PRNewswire/ -- Two newly published studies add to an already robust body of clinical research on prunes' myriad health benefits. This tasty pantry staple is a nutritional powerhouse that may benefit gut microbiome health, bone health, heart health and more. 

Key Points: 
  • This tasty pantry staple is a nutritional powerhouse that may benefit gut microbiome health, bone health, heart health and more.
  • Prunes are a nutritional powerhouse that may benefit gut microbiome health, bone health, heart health and more.
  • The increase of belly fat is common in postmenopausal women and when excessive, can be a risk factor for cardiovascular disease.
  • Findings from this research show a daily diet that includes prunes may help reduce that belly fat."

Low-Dose Naltrexone in Gastroenterology: A Bonafide ‘Wonder Drug’

Retrieved on: 
Vendredi, mai 3, 2024
Defecation, Irritable bowel syndrome, Ulcerative colitis, Inflammation, Gastroenterology, Crohn's disease, RLS, Restless legs syndrome, Research, IBD, Inflammatory bowel disease, Flatulence, Psoriasis, Health, Immune system, LDN, IBS, Medical device

Dr. Weinstock's insightful piece sheds light on the potential of LDN as a novel therapeutic approach in the field of gastroenterology.

Key Points: 
  • Dr. Weinstock's insightful piece sheds light on the potential of LDN as a novel therapeutic approach in the field of gastroenterology.
  • Low-dose naltrexone, traditionally known for its role in managing opioid and alcohol dependence, has emerged as a compelling option for addressing various gastrointestinal conditions.
  • Furthermore, Dr. Weinstock highlights the need for further research and clinical trials to fully elucidate LDN's therapeutic potential in gastroenterology.
  • For more information on Dr. Leonard Weinstock's insights into low-dose naltrexone in gastroenterology, please read his full article here .

Leading-Edge Technologies, Data and Insights: Bio-IT World Conference & Expo Highlights the Drivers of Precision Medicine Innovation

Retrieved on: 
Jeudi, mars 14, 2024
Molecule, Learning Technology Partners, Personalized medicine, Organization, Conference, Innovation, Biotechnology, AstraZeneca, Partnering, Convention, Virtual humans, Data science, Drug discovery, RWE, Bias, Shape, Social media, Stargate Atlantis, RWD, Transformation, Bristol Myers Squibb, Digital twin, Student, LDN, Investment, Vacuum, RDN, Water, Machine learning, MD Anderson Cancer Center, Pharmaceutical industry

BOSTON, March 14, 2024 /PRNewswire/ -- Life science innovation doesn't happen in a vacuum. It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.

Key Points: 
  • It results from leaders with complementary expertise partnering across organizations and countries to build on data, research, and case studies—all facilitated by leading-edge technologies.
  • From April 15-17, more than 3,000 pharmaceutical, biotechnology and IT leaders will gather for the 23rd annual Bio-IT World Conference & Expo in Boston to put this model into action.
  • "Precision medicine is at a tipping point as both scientific and computing capabilities explode," said Cindy Crowninshield, RDN, LDN, Executive Event Director.
  • This year, the Bio-IT World conference will focus on how to keep the creative pipeline flowing by bringing rising scientists into the fold.

New FMI Report: Food Industry Committed to Health and Well-Being Initiatives

Retrieved on: 
Jeudi, février 15, 2024
Men, Retail, Health, Family, Consumer, Restaurant, Bar, Other Retail, Supermarket, Other Consumer, Specialty, Fitness & Nutrition, Women, Food, Beverage, Organic Food, Well, CNAME record, American Heart Association, Multimedia, RDN, Marketing, Food industry, Pharmacy, LDN, Sugar, Practitioner, Health promotion, Nutrient, Nursing, Organization, FMI, Science, Sodium, Medicine

As Americans’ interest in nutrition and healthy eating has increased in recent years, companies across the food industry have implemented numerous initiatives to support consumers’ health needs and priorities, according to FMI – The Food Industry Association’s new Food Industry Contributions to Health and Well-Being 2024 report.

Key Points: 
  • As Americans’ interest in nutrition and healthy eating has increased in recent years, companies across the food industry have implemented numerous initiatives to support consumers’ health needs and priorities, according to FMI – The Food Industry Association’s new Food Industry Contributions to Health and Well-Being 2024 report.
  • While health and well-being has always been a key priority, nutrition and overall health has become the top focus for the food industry this year.
  • Food as Medicine programs that connect the science of food and nutrition to improved health for customers, employees and communities, are also gaining momentum across the food industry.
  • Members of the media may contact FMI for a gratis copy of the Food Industry Contributions to Health and Well-Being 2024 report.

Accelerating Drug Discovery: Life Science and IT Leaders Explore the Power of Artificial Intelligence April 15-17 in Boston

Retrieved on: 
Mercredi, janvier 24, 2024
Knowledge, Synthetic media, Development, Merck & Co., Biotechnology, LDN, Medication, Digitization, Intelligence, Personalized medicine, Novartis, AI, Hub, Digitalization, Drug discovery, Automation, Generative, Conference, RDN, FAIR data, Biomedical Research, Machine learning, AbbVie, Janssen Pharmaceuticals, Merck, Data science, Terra, Vertex Pharmaceuticals, Medical device

BOSTON, Jan. 24, 2024 /PRNewswire/ -- Recognizing the critical role of artificial intelligence in accelerating drug discovery, Bio-IT World Conference & Expo is offering expanded content on this pivotal technology at its 23rd annual event.

Key Points: 
  • Convening April 15-17, 2024 in Boston, Bio-IT World will bring together more than 3,000 attendees seeking to collaborate with other top pharmaceutical, biotech and technology leaders.
  • Three of the 10 technology conference tracks, comprising dozens of sessions, will be AI-focused—covering Generative AI, AI for Drug Discovery and Development, and AI for Oncology, Precision Medicine, and Health.
  • "The integration of AI and machine learning (ML) in life sciences offers unparalleled advantages—speeding the identification of drug candidates, improving precision in treatment approaches, and optimizing experimental processes.
  • These technologies promise more rapid therapeutic advances," said Cindy Crowninshield, RDN, LDN, Executive Event Director.

New EHR Integration Simplifies Provider Workflow for Patients Living With Diabetes

Retrieved on: 
Mardi, novembre 21, 2023
Software, Research, Professional Services, Philanthropy, Data Management, Technology, Health Technology, Data Analytics, Science, Practice Management, Other Philanthropy, Health, Diabetes, Data management, EHR, PDF, CPT, Patient, Multimedia, Electronic health record, Health information management, Prescription, Single sign-on, SSO, Data, Vital signs, Pharmaceutical industry, RD, LDN, Tide pool

Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce the launch of its state-of-the-art Electronic Health Record (EHR) integration for its cutting-edge diabetes data visualization platform.

Key Points: 
  • Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce the launch of its state-of-the-art Electronic Health Record (EHR) integration for its cutting-edge diabetes data visualization platform.
  • This groundbreaking integration marks a significant advancement in the company’s mission to empower healthcare providers and people living with diabetes to make their data more accessible, actionable, and meaningful.
  • This enables providers to interpret diabetes data and provide data-driven diabetes care efficiently by viewing Tidepool+ reports directly in patients’ charts.
  • Tidepool+ data can be conveniently imported into the EHR as discrete summary data or static PDF reports within a patient’s chart.

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Retrieved on: 
Lundi, novembre 6, 2023
Avalon, Modified vaccinia Ankara, Autoimmunity, American Association for Cancer Research, Hepatology, Vaccine, Liver, Immunogenicity, LDN, PD-1, University, CHB, Research, Barinthus, Immune system, COVID-19, Efficacy, MVA, Hepatitis, Repeat, Hepatitis B, Infection, Cancer, HBsAg, Patient, Asian Liver Center, HBV, AASLD, Pharmaceutical industry, Oxford–AstraZeneca COVID-19 vaccine, Safety

The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines. The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023. As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com.

Key Points: 
  • The company also announced today that it has changed its name to Barinthus Biotherapeutics plc to represent the evolution and expansion of its focus beyond vaccines.
  • The company expects to begin trading under its new name and ticker (Nasdaq: BRNS) effective as of November 7, 2023.
  • As part of the rebranding, the company has also updated its website -- learn more at www.barinthusbio.com .
  • “Today the company is focused on the development of novel T cell immunotherapeutic candidates, which evolved out of that initial vaccine research.

The Institute for Value-Based Medicine® from The American Journal of Managed Care® Hosts Event to Address Food Insecurity, Obesity and Chronic Conditions in Louisiana

Retrieved on: 
Jeudi, novembre 2, 2023
Across, MMM, Public health, Louisiana State University Agricultural Center, Food security, Health, Obesity, MPH, LDN, State, Diabetes, Food, Organization, Population health, Pennington Biomedical Research Center, Governing boards of colleges and universities in the United States, Dementia, Ochsner Health System, Death, Quality of life, Conditional sentence, School, The American Journal of Managed Care, Health equity, Food science, Partnership, Poverty, Strategic planning, Lead, Nutrition, RDN, FACP, Cancer, American Journal, Student Success Act, Pennington, Louisiana State University, LSU, Cardiovascular disease, IVBM, Pharmaceutical industry, Management, Nursing, MD, Wellness

The Institute for Value-Based Medicine (IVBM) is renowned for promoting value-based care and advancing healthcare practices.

Key Points: 
  • The Institute for Value-Based Medicine (IVBM) is renowned for promoting value-based care and advancing healthcare practices.
  • This upcoming event brings together panels of distinguished healthcare and community experts who will delve into the latest innovations of value-based care.
  • Together, they will discuss ways to address food insecurity, obesity and chronic conditions, which are major challenges in Louisiana.
  • Lacking access to nutritional food can lead to or worsen chronic conditions, or those that require ongoing medical attention.

How AI is Transforming Drug Discovery: Bio-IT World Europe Participants to Share Groundbreaking Advances 29-30 November in London

Retrieved on: 
Lundi, novembre 6, 2023
Digital, China Earthquake Networks Center, AstraZeneca, Expert system, Health care, Government, LDN, Conference, Organization, Research, Drug development, Clarivate, Artificial intelligence, MOSAIC, Medicine, Drug discovery, Machine learning, Personalized medicine, RDN, AI, Potential, D, Queen Mary University of London, Medical device, Cancer

LONDON, Nov. 6, 2023 /PRNewswire-PRWeb/ -- The life sciences profession is in the midst of a profound transformation, guided by the revolutionary force of artificial intelligence (AI), and especially predictive and generative AI models. These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.

Key Points: 
  • These state-of-the-art technologies are leading the charge—expediting drug discovery and development, catalyzing innovation, and uncovering potential new therapies for cancer, heart disease, and more.
  • "The bio-IT community has always been at the forefront of leveraging AI with the important goal of increasing therapeutic efficacy."
  • In parallel, generative AI refines molecular design with exquisite precision, drastically curtailing the time and resources necessary for drug development.
  • "As general interest in AI explodes, our distinguished speakers have valuable information to share about its evolving role in precision medicine."

Better Therapeutics to Participate in the American College of Lifestyle Medicine’s 2023 Annual Conference

Retrieved on: 
Jeudi, octobre 26, 2023
Mental Health, Medical Devices, Diabetes, Health Technology, Cardiology, Biotechnology, Managed Care, Health, General Health, Medical Affairs Bureau, FDA, American College, PDT, Food, Physician, LDN, MD, Conference, Doctor of Philosophy, Type 2 diabetes, ACLM, Medicine, T2D, Better, CBT, RDN, Therapy, Patient, Food and Drug Administration, MST, Cognitive behavioral therapy, Pharmaceutical industry

Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced its participation in the American College of Lifestyle Medicine's (ACLM) 2023 Lifestyle Medicine Annual Conference (LM2023), to be held October 29 to November 1, 2023, in Denver, Colorado.

Key Points: 
  • Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced its participation in the American College of Lifestyle Medicine's (ACLM) 2023 Lifestyle Medicine Annual Conference (LM2023), to be held October 29 to November 1, 2023, in Denver, Colorado.
  • Better Therapeutics’ platinum sponsorship of LM2023 reflects the company’s shared commitment to showcasing evidence-based solutions that restore health for those living with chronic conditions.
  • Attendees will have the opportunity to experience the product firsthand and learn more about its clinical benefits at the Better Therapeutics exhibition booth.
  • For more information about LM2023, visit: https://lifestylemedicine.org/project/lm2023/
    For more information about AspyreRx, visit: www.aspyrerx.com .